Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H1 2017’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

– The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects

– The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Amgen Inc

arGEN-X BV

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CSL Ltd

Genosco Inc

Hansa Medical AB

Immunomedics Inc

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Merck & Co Inc

Momenta Pharmaceuticals Inc

Novartis AG

Pfizer Inc

PhytoHealth Corp

Protalex Inc

Rigel Pharmaceuticals Inc

UCB SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development

3SBio Inc

Amgen Inc

arGEN-X BV

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CSL Ltd

Genosco Inc

Hansa Medical AB

Immunomedics Inc

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Merck & Co Inc

Momenta Pharmaceuticals Inc

Novartis AG

Pfizer Inc

PhytoHealth Corp

Protalex Inc

Rigel Pharmaceuticals Inc

UCB SA

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles

ARGX-113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-655064 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fostamatinib disodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GL-2045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2285921 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hetrombopag Olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

letolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-254 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-281 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8723 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHN-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRTX-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rozanolixizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKIO-703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

thrombopoietin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veltuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones

Featured News & Press Releases

Dec 01, 2016: argenx to provide update on ARGX-113 during American Society of Hematology Annual Meeting

Sep 22, 2016: argenx provides update on lead program ARGX-113 at R&D day in New York

Sep 15, 2016: Rigel Restructures to Focus on Fostamatinib Commercialization

Aug 30, 2016: Rigel Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP

Aug 25, 2016: Health Canada issues advisory on REVOLADE citing risk of severe hepatotoxicity

Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder

May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association

Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP

Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP

Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag

Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP

Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP

Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder

Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by 3SBio Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Amgen Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by arGEN-X BV, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Bristol-Myers Squibb Company, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by CSL Ltd, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Genosco Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Hansa Medical AB, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Immunomedics Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Merck & Co Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Momenta Pharmaceuticals Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Novartis AG, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pfizer Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by PhytoHealth Corp, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Protalex Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Rigel Pharmaceuticals Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by UCB SA, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports